Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Site-Directed Mutagenesis at the Molybdenum Pterin Cofactor Site of the Human Aldehyde Oxidase: Interrogating the Kinetic Differences Between Human and Cynomolgus Monkey

Armina Abbasi, Carolyn A. Joswig-Jones and Jeffrey P. Jones
Drug Metabolism and Disposition December 2020, 48 (12) 1364-1371; DOI: https://doi.org/10.1124/dmd.120.000187
Armina Abbasi
Department of Chemistry, Washington State University, Pullman, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn A. Joswig-Jones
Department of Chemistry, Washington State University, Pullman, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey P. Jones
Department of Chemistry, Washington State University, Pullman, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    The time course plot of the product formation under anaerobic conditions using glucose oxidase to remove oxygen (as described in Materials and Methods) is presented for O6BG in hAO (A), O6BG in mAO (B), dantrolene in hAO (C), and dantrolene in mAO (D). Saturating concentration (five times the Km) of both oxidative (O6BG, 200 μM) and reductive (dantrolene, 30 μM) substrates were used for these kinetic assays. The kinetic models used in fitting these data sets are presented as blue insets, and the R2 values are mentioned on the bottom right side of each graph. The MAM was used for (A), and the Michaelis-Menten linear model was used for (B–D). Models were selected according to the kinetic trend of the product formation in each data set.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    (A) The nitro reduction pathway: six electrons are required for a full nitro reduction, but nitroso and hydroxylamine intermediates could also be formed during this process. (B) A schematic presentation of the anaerobic AO catalytic cycle for O6BG as the oxidative substrate and dantrolene as the reductive substrate. The electron flow pathway from the MoCo site to the FAD site through the two iron-sulfur clusters is presented with a dashed arrow. The electron leakage through nitroso and hydroxylamine intermediates formed as a result of incomplete nitro reduction can pose a risk of TDI of the enzyme (orange dotted arrow). However, this is not the case for O6BG oxidation by AO.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    The time course plot of the ADNTN formation under anaerobic conditions using a saturating amount of O6BG (200 μM) as the oxidative substrate and dantrolene as the reductive substrate (30 μM). A glucose oxidase system was used to remove oxygen (as described in Materials and Methods) in all of the anaerobic reactions. The reductive half-reaction remained linear and was fit to the Michaelis-Menten model in all the mutants, F885L (black, R2 = 0.98), V811A (magenta, R2 = 0.95), and FLVA (purple, R2 = 0.96), similar to hAO (red, R2 = 0.98) and mAO (blue, R2 = 0.91).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    The time course plot of 8-oxo-O6BG formation by hAO (A), mAO (B), F885L (C), V811A (D), and FLVA double mutant (E) under anaerobic conditions using saturating concentration of O6BG (200 μM) and dantrolene (30 μM) is presented here. The data for all the enzymatic reactions were fit to the MAM, except for mAO, for which the linear Michaelis-Menten model was used.

Tables

  • Figures
    • View popup
    TABLE 1

    The human to monkey (hAO#mAO) mutants were made using the primers, DNA templates, and the sequencing primers as described

    Plasmid (hAO#mAO)PrimerDNA templateSequencing primer
    F885LFW: 5′-cag​acc​cat​ttc​aat​aac​taa​cag​gct​ttc​atc​cag​g-3′pTHco-AOX15′-att​gtt​gcc​agc​aca​ctg​aa-3′ (nucleotides 2401–2800)
    RV: 5′-cct​gga​tga​aag​cct​gtt​agt​tat​tga​aat​ggg​tct​g-3′
    V811AFW: 5′-aat​aat​acc​ggt​ttt​cag​cgc​ttt​acc​acc​aaa​tgc​acc-3′pTHco-AOX1
    RV: 5′-ggt​gca​ttt​ggt​ggt​aaa​gcg​ctg​aaa​acc​ggt​att​att-3′
    FLVAFW: 5′-aat​aat​acc​ggt​ttt​cag​cgc​ttt​acc​acc​aaa​tgc​acc-3′F885L
    RV: 5′-ggt​gca​ttt​ggt​ggt​aaa​gcg​ctg​aaa​acc​ggt​att​att-3′
    • View popup
    TABLE 2

    A comparison between the rate of product formation between the two species as well as the mutants under anaerobic conditions using a glucose oxidase system as described in the Materials and Methods section.

    MAM was the model of choice in fitting the O6BG (200 μM) product formation for hAO and all the mutants and Michaelis-Menten linear model was used to fit the O6BG product formation in mAO as well as the product formation for dantrolene (30 μM) in both species and the mutants.

    Rate of 8-oxo-O6BG formationRate of ADNTN formation
    k3_oxk4k5k3_red
    min−1min−1min−1min−1
    hAO110 ± 20.70.160 ± 0.04949.28 ± 2.030.659 ± 0.0182
    mAO2.19 ± 0.0696——0.156 ± 0.00876
    F885L38.7 ± 3.850.0388 ± 0.01447.90 ± 2.710.701 ± 0.0193
    V811A40.7 ± 8.510.158 ± 0.04862.95 ± 0.5220.336 ± 0.0143
    FLVA30.4 ± 5.020.0659 ± 0.02897.50 ± 1.370.486 ± 0.0199
    • View popup
    TABLE 3

    The change in the ratio of the concentration of the oxidative to reductive product (OAR) with time under anaerobic conditions (as described in the Materials and Methods section) and saturating amount of the oxidative and reductive substrates, O6BG (200 μM) and dantrolene (30 μM), respectively

    Time, min[8-oxo-O6BG]/[ADNTN]
    hAOmAOF885LV811AFLVA
    μM/μMμM/μMμM/μMμM/μMμM/μM
    0.255.6 ± 19.34.41 ± 0.62286.0 ± 42.246.1 ± 23.921.7 ± 4.54
    371.8 ± 26.83.59 ± 1.3839.8 ± 8.2034.4 ± 9.7028.8 ± 1.54
    1071.3 ± 16.94.43 ± 1.3242.1 ± 7.2239.8 ± 8.4539.5 ± 2.71
    2061.0 ± 12.05.99 ± 0.88147.2 ± 2.3137.4 ± 8.0940.3 ± 2.51
    3052.7 ± 5.685.41 ± 1.4843.4 ± 1.3433.8 ± 4.4140.6 ± 3.53
    4539.3 ± 8.136.78 ± 1.6438.6 ± 3.6727.7 ± 2.5438.1 ± 5.25
    6033.5 ± 5.947.63 ± 1.7234.6 ± 3.2423.9 ± 1.7934.8 ± 6.57
    9025.3 ± 3.307.90 ± 1.6026.7 ± 2.4019.5 ± 1.0929.5 ± 4.25
    12020.6 ± 2.578.53 ± 2.6222.3 ± 2.7116.3 ± 0.87521.4 ± 0.972
    Average50.3 ± 20.85.83 ± 1.8342.3 ± 18.231.0 ± 9.8532.8 ± 7.70
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 48 (12)
Drug Metabolism and Disposition
Vol. 48, Issue 12
1 Dec 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Site-Directed Mutagenesis at the Molybdenum Pterin Cofactor Site of the Human Aldehyde Oxidase: Interrogating the Kinetic Differences Between Human and Cynomolgus Monkey
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Kinetic Differences Between Human and Cynomolgus Monkey Aldehyde Oxidase

Armina Abbasi, Carolyn A. Joswig-Jones and Jeffrey P. Jones
Drug Metabolism and Disposition December 1, 2020, 48 (12) 1364-1371; DOI: https://doi.org/10.1124/dmd.120.000187

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Kinetic Differences Between Human and Cynomolgus Monkey Aldehyde Oxidase

Armina Abbasi, Carolyn A. Joswig-Jones and Jeffrey P. Jones
Drug Metabolism and Disposition December 1, 2020, 48 (12) 1364-1371; DOI: https://doi.org/10.1124/dmd.120.000187
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics